Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil

Li,Zhaoyang; Wang,Ning; Huang,Changxin; Bao,Yanhong; Jiang,Yiqian; Zhu,Guiting

doi:10.3892/ol.2016.5390

Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil

Authors:
- Zhaoyang Li
- Ning Wang
- Changxin Huang
- Yanhong Bao
- Yiqian Jiang
- Guiting Zhu
View Affiliations

Affiliations: Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, P.R. China, Department of Ultrasound, Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, P.R. China, Second Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Department of Radiation Oncology, The First People's Hospital of Xiaoshan, Hangzhou, Zhejiang 311200, P.R. China
Published online on: November 16, 2016 https://doi.org/10.3892/ol.2016.5390
Pages: 483-487

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is the third most common type of cancer in men and women. Chemotherapy is an important treatment strategy for patients with terminal stage cancer. However, the development of drug resistance hampers the effectiveness of chemotherapy. Therefore, an effective therapeutic approach to target chemoresistance‑associated cellular molecules is required. In the present study, drug‑resistant human colorectal cancer HCT116 cells were developed by treating HCT116 cells with increasing concentrations of 5‑fluorouracil (5‑FU). The present study indicated that the drug-resistance cells (DRC) were resistant to 5-FU compared with parental HCT116 cells by detecting cell survival using an MTT assay. Additionally, the expression of the chemoresistance‑associated protein caveolin‑1 (Cav‑1) was assessed by reverse transcription‑quantitative polymerase chain reaction and western blotting. The results revealed that the Cav‑1 expression level was significantly higher in DRC compared with that in the parental HCT116 cells. Next, Cav‑1 was silenced by small interfering RNA (siRNA) or was inhibited with its specific inhibitor methyl β‑cyclodextrin (MCD). MTT assay demonstrated that Cav‑1 siRNA and MCD resensitized DRC to 5‑FU. These data reveal that Cav‑1 was involved in the development of resistance, suggesting that Cav‑1 is a potential target for the treatment of colorectal cancer chemoresistance. In addition, 5-FU combined with Cav-1 siRNA or its specific inhibitor may increase the effectiveness of the treatment strategy.

View Figures

View References

1	Defining Cancer, . National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancerAccessed June 10, 2014.
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Wu J, Qiu T, Pan P, Yu D, Ju Z, Qu X, Gao X, Mao C and Wang L: Detection of serum anti-p53 antibodies from patients with colorectal cancer in china using a combination of p53- and phage-ELISA. Asian Pac J Cancer Prev. 12:2921–2924. 2011.PubMed/NCBI
4	Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E and Labhasetwar V: Drug resistance in breast cancer cells: Biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm. 7:2334–2348. 2010. View Article : Google Scholar : PubMed/NCBI
5	Seddon AM, Casey D, Law RV, Gee A, Templer RH and Ces O: Drug interactions with lipid membranes. Chem Soc ReV. 38:2509–2519. 2009. View Article : Google Scholar : PubMed/NCBI
6	Righetti SC, Perego P, Carenini N, Corna E, Dal Bo L, Cedrola S, La Porta CA and Zunino F: Molecular alterations of cells resistant to platinum drugs: Role of PKCalpha. Biochim Biophys Acta. 1763:93–100. 2006. View Article : Google Scholar : PubMed/NCBI
7	Dai Z, Huang Y and Sadée W: Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 4:1347–1356. 2004.PubMed/NCBI
8	Rossi S: Australian Medicines Handbook (2013 edition). The Australian Medicines Handbook Unit Trust; Adelaide: 2013
9	Tolba MF and Abdel-Rahman SZ: Pterostilbine, an active component of blueberries, sensitizes colon cancer cells to 5-fluorouracil cytotoxicity. Sci Rep. 5:152392015. View Article : Google Scholar : PubMed/NCBI
10	Ohtsu A: Chemotherapy for metastatic gastric cancer: Past, present, and future. J Gastroenterol. 43:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
11	Williams TM and Lisanti MP: The caveolin proteins. Genome Biol. 5:2142004. View Article : Google Scholar : PubMed/NCBI
12	Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF and Lisanti MP: Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 271:2255–2261. 1996. View Article : Google Scholar : PubMed/NCBI
13	Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF and Lisanti MP: Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA. 93:131–135. 1996. View Article : Google Scholar : PubMed/NCBI
14	Hill MM, Bastiani M, Luetterforst R, Kirkham M, KirKham A, Nixon SJ, Walser P, Abankwa D, Oorschot VM, Martin S, et al: PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 132:113–124. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hansen CG and Nichols BJ: Exploring the caves: Cavins, caveolins and caveolae. Trends Cell Biol. 20:177–186. 2010. View Article : Google Scholar : PubMed/NCBI
16	Briand N, Dugail I and Le Lay S: Cavin proteins: New players in the caveolae field. Biochimie. 93:71–77. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010. View Article : Google Scholar : PubMed/NCBI
18	Li S, Couet J and Lisanti MP: Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J BiolChem. 271:29182–29013. 1996.
19	Selleri S, Arnaboldi F, Palazzo M, Hussein U, Balsari A and Rumio C: Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br J Dermatol. 153:506–513. 2005. View Article : Google Scholar : PubMed/NCBI
20	Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC and Clarke R: Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J BiolChem. 282:5934–5943. 2007.
21	Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, Man K, Wong AS, Ng IO and Yam JW: Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol. 226:645–653. 2012. View Article : Google Scholar : PubMed/NCBI
22	Tang Y, Zeng X, He F, Liao Y, Qian N and Toi M: Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Med Oncol. 29:977–984. 2012. View Article : Google Scholar : PubMed/NCBI
23	Selleri S, Arnaboldi F, Palazzo M, Hussein U, Balsari A and Rumio C: Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy. Br J Dermatol. 153:506–513. 2005. View Article : Google Scholar : PubMed/NCBI
24	Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC and Clarke R: Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J BiolChem. 282:5934–5943. 2007.
25	Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA and Theodorescu D: Src and Caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathways in bladder cancer. Cancer Res. 71:832–841. 2011. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV and Bhat MK: Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: Molecular events involved. PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
28	American Cancer Society, . Cancer Facts & Figures 2014. American Cancer Society; Atlanta, GA: 2014
29	Colon Cancer Treatment (PDQ^®)–Patient Version. National Cancer Institute; https://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq#section/allAccessed June 29, 2014.
30	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–47. 2010. View Article : Google Scholar : PubMed/NCBI
31	Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
32	Germann UA and Chambers TC: Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology. 27:31–60. 1998. View Article : Google Scholar : PubMed/NCBI
33	Xu Y, Zhi F, Xu G, Tang X, Lu S, Wu J and Hu Y: Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416. Biosci Rep. 32:559–566. 2012. View Article : Google Scholar : PubMed/NCBI
34	Nimri L, Barak H, Graeve L and Schwartz B: Restoration of caveolin-1 expression suppresses growth, membrane-type-4 metalloproteinase expression and metastasis-associated activities in colon cancer cells. Mol Carcinog. 52:859–870. 2013. View Article : Google Scholar : PubMed/NCBI
35	Bender FC, Reymond MA, Bron C and Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60:5870–5888. 2000.PubMed/NCBI